Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00460798
Status:
COMPLETED
Last Update Posted:
2010-11-16
First Post:
2007-04-13
Brief Title:
SUTENT In The First Line Treatment Of Renal Cell Carcinoma
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Non-Interventional Study With SUTENT In The First Line Treatment Of Renal Cell Cancer
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SUNIKA
Brief Summary:
This non-interventional study includes patients with advanced andor metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before The aim of the trial is to increase knowledge about quality of life safety efficacy and tolerability under conditions of routine use of Sutent The individual observation period of each patient will be
1 year
1 year
Detailed Description:
The Statistical Analysis Plan provides detailed specification of the analysis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None